Karen Reckamp, MD, MS (@reckampk) 's Twitter Profile
Karen Reckamp, MD, MS

@reckampk

Medical Oncologist, lung cancer, Director, Division of Medical Oncology Associate Director of Clinical Research Cedars-Sinai Cancer

ID: 1222949137869463552

calendar_today30-01-2020 18:26:24

71 Tweet

1,1K Takipçi

138 Takip Edilen

Karen Reckamp, MD, MS (@reckampk) 's Twitter Profile Photo

I’ll be at #ASCO22 presenting the latest treatment options for common + less common targetable #biomarkers for advanced #NSCLC: #EGFR, KRAS, and #HER2 alongside Todd M. Bauer @NarjustDumaMD Karen Reckamp, MD, MS. Join us Sat June 4 in Chicago #lungcancer tinyurl.com/4p8bnt56

Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. fal.cn/3pavG Karen Reckamp, MD, MS Roy Herbst #lcsm

Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

NRG1 fusions are part of the NSCLC drivers family!! Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population (n=83), ~50% being NSCLC. ORR=34% overall and 35% in NSCLC. Median DoR 9.1 mo and favorable safety profile. #ASCO22

NRG1 fusions are part of the NSCLC drivers family!! Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population (n=83), ~50% being NSCLC. ORR=34% overall and 35% in NSCLC. Median DoR 9.1 mo and favorable safety profile. #ASCO22
Cancer at Cedars-Sinai (@cscancercenter) 's Twitter Profile Photo

#CedarsSinaiCancer at #ASCO22. Dr. Karen Reckamp Karen Reckamp, MD, MS is co-author on “Characterization of MET exon 14 skipping alterations in non–small cell lung cancer using whole transcriptome sequencing.”ASCO Cedars-Sinai Academic Medicine @CSCancerCare #NSCLC

#CedarsSinaiCancer at #ASCO22.   Dr. Karen Reckamp <a href="/ReckampK/">Karen Reckamp, MD, MS</a> is co-author on “Characterization of MET exon 14 skipping alterations in non–small cell lung cancer using whole transcriptome sequencing.”<a href="/ASCO/">ASCO</a> <a href="/CedarsSinaiMed/">Cedars-Sinai Academic Medicine</a> @CSCancerCare #NSCLC
Cancer at Cedars-Sinai (@cscancercenter) 's Twitter Profile Photo

#CedarsSinaiCancer at #ASCO22. Dr. Karen Reckamp Karen Reckamp, MD, MS is co-author on the poster “A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer: SYMPHONY trial in progress.”ASCO Cedars-Sinai Academic Medicine @CSCancerCare #NSCLC

#CedarsSinaiCancer at #ASCO22.   Dr. Karen Reckamp <a href="/ReckampK/">Karen Reckamp, MD, MS</a> is co-author on the poster “A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer: SYMPHONY trial in progress.”<a href="/ASCO/">ASCO</a> <a href="/CedarsSinaiMed/">Cedars-Sinai Academic Medicine</a> @CSCancerCare #NSCLC
Balazs Halmos (@balazshalmosmd) 's Twitter Profile Photo

Looking for a great Metworking opportunity? Come to our posters on METex14 w excellent lead authors Jennifer A. Marks, MD and #ASCO22 Merit awardee So Yeon Kim ! (Crediting Stephen V Liu, MD for his great leadership on our Caris POA + coining the new and now licensed term: #Metwork)

Looking for a great Metworking opportunity?
Come to our posters on METex14 w excellent lead authors <a href="/jennifermarksmd/">Jennifer A. Marks, MD</a> and #ASCO22 Merit awardee <a href="/Sokim_33/">So Yeon Kim</a> ! 

(Crediting <a href="/StephenVLiu/">Stephen V Liu, MD</a> for his great leadership on our Caris POA + coining the new and now licensed term: #Metwork)
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

#ASCO22 Pleased to present the EGFR-mt subgrp analysis of PACIFIC in which we see no diffs in PFS/OS with durva v PBO, &no concerning safety signals You know you’ve made it when ⁦@dhjutsw1⁩ comes to your poster ⭐️ ⁦⁦Beaumont RCSI Cancer Centre⁩ ⁦Johns Hopkins Thoracic Oncology

#ASCO22 

Pleased to present the EGFR-mt subgrp analysis of PACIFIC in which we see no diffs in PFS/OS with durva v PBO, &amp;no concerning safety signals 

You know you’ve made it when ⁦@dhjutsw1⁩ comes to your poster ⭐️ 

⁦⁦<a href="/CancerCentreIre/">Beaumont RCSI Cancer Centre</a>⁩ ⁦<a href="/HopkinsThoracic/">Johns Hopkins Thoracic Oncology</a>⁩
Karen Reckamp, MD, MS (@reckampk) 's Twitter Profile Photo

It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A ASCO dailynews.ascopubs.org/do/10.1200/ADN…

Cancer at Cedars-Sinai (@cscancercenter) 's Twitter Profile Photo

Dr. Karen Reckamp Karen Reckamp, MD, MS, Dr. Amin Mirhadi Amin Mirhadi & Dr. Imai Taryne will chair the Curio Science interactive workshop “Opinions in Non-Targetable Early Stage #NSCLC” on 6/14 at 6-8pm PT. Please register via: [email protected]. Cedars-Sinai #CedarsSinaiCancer

Dr. Karen Reckamp <a href="/ReckampK/">Karen Reckamp, MD, MS</a>, Dr. Amin Mirhadi <a href="/aminmirhadi/">Amin Mirhadi</a> &amp; Dr. Imai Taryne will chair the <a href="/_CurioScience_/">Curio Science</a> interactive workshop “Opinions in Non-Targetable Early Stage #NSCLC” on 6/14 at 6-8pm PT. Please register via: workshops@curio-science.com. <a href="/CedarsSinai/">Cedars-Sinai</a> #CedarsSinaiCancer
Karen Reckamp, MD, MS (@reckampk) 's Twitter Profile Photo

Congratulations to the Lung-MAP team for 10 years of dedication and success. Teamwork and commitment to patients is the key. Excellent talk by Roy Herbst at SWOG. It takes a village. David Gandara Jyoti D Patel Mary Redman, Vali Papadimitrakopoulou and so many others. #SWOG #LCSM

Congratulations to the <a href="/LungMAP/">Lung-MAP</a> team for 10 years of dedication and success. Teamwork and commitment to patients is the key. Excellent talk by <a href="/DrRoyHerbstYale/">Roy Herbst</a> at SWOG. It takes a village. <a href="/drgandara/">David Gandara</a> <a href="/JPatelMD/">Jyoti D Patel</a> Mary Redman, Vali Papadimitrakopoulou and so many others. #SWOG #LCSM
Christine Lovly, MD, PhD, FASCO (@christine_lovly) 's Twitter Profile Photo

👏 Attn: We have a new AACR President Patricia M. LoRusso - clinician scientist extraordinaire, Dr. PatLoRusso! Dr. LoRusso outlined some of her priorities today; 🎯 ⬆️ outreach to patients 🎯 ⬆️ recruitment/retention of underrepresented researchers 🎯 AACR Center for Cancer Clinical Trials #AACR24

👏 Attn: We have a new <a href="/AACRPres/">AACR President Patricia M. LoRusso</a> - clinician scientist extraordinaire, Dr. PatLoRusso! Dr. LoRusso outlined some of her priorities today;
🎯 ⬆️ outreach to patients
🎯 ⬆️ recruitment/retention of underrepresented researchers 
🎯 <a href="/AACR/">AACR</a> Center for Cancer Clinical Trials
#AACR24
Karen Reckamp, MD, MS (@reckampk) 's Twitter Profile Photo

Join us for the Year in Review Live Webinar | Targeted Therapy for Non-Small Cell Lung Cancer Edition on May 8, 4:30-6pm ET. Dr. Justin Gainor and I will discuss the latest updates with Dr. Neil Love to improve patient care and outcomes. #LCSM m.researchtopractice.com/Webinars/YiR24…